Page last updated: 2024-08-21

cyproterone acetate and Carcinoma in Situ

cyproterone acetate has been researched along with Carcinoma in Situ in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bosland, MC; Kroes, R; Prinsen, MK1
Lotti, T; Montironi, R; Polito, M; Prezioso, D1

Trials

1 trial(s) available for cyproterone acetate and Carcinoma in Situ

ArticleYear
Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group.
    Urologia internationalis, 1998, Volume: 60 Suppl 2

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cyproterone Acetate; Delayed-Action Preparations; Diagnosis, Differential; Disease-Free Survival; Drug Administration Schedule; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostatectomy; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms

1998

Other Studies

1 other study(ies) available for cyproterone acetate and Carcinoma in Situ

ArticleYear
Adenocarcinomas of the prostate induced by N-nitroso-N-methylurea in rats pretreated with cyproterone acetate and testosterone.
    Cancer letters, 1983, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Animals; Carcinoma in Situ; Cocarcinogenesis; Cyproterone; Cyproterone Acetate; Male; Methylnitrosourea; Models, Biological; Neoplasm Metastasis; Neoplasms, Experimental; Nitrosourea Compounds; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Testosterone

1983